Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

Continue reading →